Emerging drugs for the treatment of irritability associated with autism spectrum disorder

Ahmad Shamabadi,Hanie Karimi,Razman Arabzadeh Bahri,Mohsen Motavaselian,Shahin Akhondzadeh
DOI: https://doi.org/10.1080/14728214.2024.2313650
2024-02-06
Expert Opinion on Emerging Drugs
Abstract:Introduction Autism spectrum disorder (ASD) is an early-onset disorder with a prevalence of 1% among children and reported disability-adjusted life years of 4.31 million. Irritability is a challenging behavior associated with ASD, for which medication development has lagged. More specifically, pharmacotherapy effectiveness may be limited against high adverse effects (considering side effect profiles and patient medication sensitivity); thus, the possible benefits of pharmacological interventions must be balanced against potential adverse events in each patient.
pharmacology & pharmacy
What problem does this paper attempt to address?